FURIN and COVID-19: A combination TMPRSS2 inhibitors with inhibitors of Furin exhibited more potent activity against SARS‐CoV‐2 than any monotherapy,56, 66 suggesting therapeutic potential of Furin for treatment of COVID‐19.